A multi-institutional team led by Northwestern University and collaborating groups reported progress toward implantable “living pharmacies” that manufacture multiple medicines inside the body. In a Device paper, researchers engineered a wireless platform integrating engineered cells with in-situ oxygenation to keep therapeutic cell “factories” alive and producing biologics. The platform (HOBIT and a related implantable system) was described as capable of sustaining cells long enough to deliver stable levels of different therapeutics, addressing oxygen competition that typically limits production from encapsulated cell therapies. The team said their oxygenation bioelectronics approach improved cell survival and enables multiple therapies with different half-lives. If the approach holds up beyond rodent models, it could reshape chronic-treatment delivery by shifting production from repeated dosing to continuous in-body release, while also simplifying combination biologic management.